Are you Dr. Mead?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
10833 Le Conte Ave
Los Angeles, CA 90095Phone+1 310-825-5756Fax+1 310-825-5756
Summary
- Dr. Monica Mead, MD is an oncologist in Los Angeles, California. She is currently licensed to practice medicine in California.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2008 - 2011
Medical College of Georgia at Augusta UniversityClass of 2008
Certifications & Licensure
CA State Medical License 2010 - 2025
Clinical Trials
- Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy Start of enrollment: 2020 Jan 15
Publications & Presentations
PubMed
- 148 citationsChronic myeloid leukemia, version 2.2021Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia
Journal of the National Comprehensive Cancer Network. 2020-10-01 - 62 citationsBCOR regulates myeloid cell proliferation and differentiationQi Cao, Micah D. Gearhart, Sigal Gery, Seyedmehdi Shojaee, Henry Yang
Leukemia. 2016-02-05 - 21 citationsCD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.Sarah M Larson, Christopher M Walthers, Brenda Ji, Sanaz N Ghafouri, Jacob Naparstek
Cancer Discovery. 2023-03-01
Authored Content
- Measurable Residual Disease in Hematopoietic Stem Cell Transplantation-Eligible Patients with Acute Myeloid Leukemia: Clinical Significance and Promising Therapeutic StrategiesJuly 2020
